United States Biotechnology & Medical Research

Septerna Inc (SEPN)

Track

Track

Septerna Inc. experienced significant insider selling activity over the past ninety days, totaling approximately 146.5 million dollars. These transactions involved various officers and major shareholders, including RA Capital Management and Third Rock Ventures. This divestment follows the company's recent positive results financiers, while the stock price maintains a strong performance trend.
Ticker: SEPN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Septerna Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
DANIEL LONG Officer Officer
Transaction date
Proposed sale
Price
429.14
Quantity 19,031
Value US$4,833,406
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
17.42
Quantity 35,169
Value US$2,343,761
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
296.15
Quantity 3,448 +32.4%
Value US$524,753
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Sale
Price
42.50
Quantity 746,500 -50.7%
Value US$31,726,250
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Sale
Price
42.50
Quantity 746,500 -13.5%
Value US$31,726,250
RA Capital Healthcare Fund LP affiliate
Transaction date
Proposed sale
Price
48.19
Quantity 746,500
Value US$35,973,835
3.2
Third Rock Ventures V, L.P. 10% Stockholder Large shareholder
Transaction date
Proposed sale
Price
51.00
Quantity 147,200
Value US$7,507,200
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
44.00
Quantity 25,000 -12.5%
Value US$1,100,000
ELIZABETH P. BHATT Officer Officer
Transaction date
Proposed sale
Price
38.85
Quantity 29,000
Value US$1,126,650
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
34.68
Quantity 2,334 -2.4%
Value US$80,944
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
33.98
Quantity 1,000 -1.0%
Value US$33,976
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
33.99
Quantity 4,000 -2.2%
Value US$135,974
ELIZABETH P. BHATT Officer Officer
Transaction date
Proposed sale
Price
34.54
Quantity 4,000
Value US$138,160
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
34.81
Quantity 1,233 -1.3%
Value US$42,926
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
34.10
Quantity 2,100 -2.1%
Value US$71,602
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
35.18
Quantity 2,178 -73.3%
Value US$76,622
JAE KIM Officer Officer
Transaction date
Proposed sale
Price
36.61
Quantity 2,438
Value US$89,243
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
35.97
Quantity 7,000 -6.8%
Value US$251,781
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
35.10
Quantity 8,000 -7.2%
Value US$280,801
DANIEL LONG Officer Officer
Transaction date
Proposed sale
Price
36.17
Quantity 25,000
Value US$904,250
DANIEL LONG Officer Officer
Transaction date
Proposed sale
Price
36.17
Quantity 25,000
Value US$904,250
JAE KIM Officer Officer
Transaction date
Proposed sale
Price
35.26
Quantity 94,339
Value US$3,326,120
JAE KIM Officer Officer
Transaction date
Proposed sale
Price
35.26
Quantity 94,339
Value US$3,326,120
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
35.08
Quantity 6,250 -88.7%
Value US$219,224
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
34.03
Quantity 8,428
Value US$286,805
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
29.66
Quantity 2,889 -78.5%
Value US$85,696
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
28.79
Quantity 1,346 -26.8%
Value US$38,755
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
27.78
Quantity 1,700 -25.3%
Value US$47,231
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
30.06
Quantity 11,798 -93.7%
Value US$354,656
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
28.36
Quantity 11,798
Value US$334,591
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
25.86
Quantity 326 -0.2%
Value US$8,431
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
25.24
Quantity 1,101 -0.6%
Value US$27,789
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
23.76
Quantity 2,573 -1.4%
Value US$61,124
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
28.14
Quantity 66,363 -98.8%
Value US$1,867,342
Shaikhly Samira Chief People Officer Officer
Transaction date
Planned sale
Price
27.51
Quantity 4,090 -5.7%
Value US$112,496
SAMIRA SHAIKHLY Officer Officer
Transaction date
Proposed sale
Price
29.02
Quantity 76,388
Value US$2,216,780
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
29.58
Quantity 1,800 -1.0%
Value US$53,250
Bhatt Elizabeth President and COO Officer
Transaction date
Planned sale
Price
28.46
Quantity 2,200 -1.2%
Value US$62,611
ELIZABETH BHATT Officer Officer
Transaction date
Proposed sale
Price
30.30
Quantity 8,000
Value US$242,400
Long Daniel D. SVP, Drug Discovery Officer
Transaction date
Planned sale
Price
18.06
Quantity 3,501 -3.6%
Value US$63,223
DANIEL DAVID LONG Officer Officer
Transaction date
Proposed sale
Price
18.06
Quantity 3,501
Value US$63,223
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
6.93
Quantity 13,319 +12.8%
Value US$92,270
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
6.00
Quantity 41,355 +65.9%
Value US$248,130
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
5.82
Quantity 37,835 +151.9%
Value US$220,260
2.8
Ezekowitz Alan Non-Executive Director
Transaction date
Purchase
Price
6.35
Quantity 7,491 +43.0%
Value US$47,544
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.85
Quantity 3,718 +10.2%
Value US$21,750
3.5
Finer Jeffrey CEO and President Executive Director
Transaction date
Purchase
Price
5.80
Quantity 3,000 +0.4%
Value US$17,400
3.5
Finer Jeffrey CEO and President Executive Director
Transaction date
Purchase
Price
5.70
Quantity 4,000 +0.5%
Value US$22,796
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.59
Quantity 6,282 +20.9%
Value US$35,116
3.5
Finer Jeffrey CEO and President Executive Director
Transaction date
Purchase
Price
5.68
Quantity 10,000 +1.3%
Value US$56,765
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.85
Quantity 5,000 +20.0%
Value US$29,250
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.88
Quantity 14,500 +138.1%
Value US$85,234
3.6
Labrucherie Gil M Chief Financial Officer Officer
Transaction date
Purchase
Price
5.51
Quantity 10,500 +inf%
Value US$57,813
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 341,600 +30.2%
Value US$6,148,800
2.9
RA CAPITAL MANAGEMENT, L.P. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 3,828,400 +225.8%
Value US$68,911,200
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-10-01 2026-10-01 PrS Proposed sale
DANIEL LONG

Officer

Officer
19,031
429.14
US$4,833,406 		19,031 429.14 US$4,833,406
2026-10-01 2026-10-01 PrS Proposed sale
SAMIRA SHAIKHLY

Officer

Officer
35,169
17.42
US$2,343,761 		35,169 17.42 US$2,343,761
2026-09-03 2026-09-01 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
3,448 +32.4%
296.15
US$524,753 		3,448 +32.4% 296.15 US$524,753
2026-08-14 2026-08-12 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
746,500 -50.7%
42.50
US$31,726,250 		746,500 -50.7% 42.50 US$31,726,250
2026-08-14 2026-08-12 S Sale
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
746,500 -13.5%
42.50
US$31,726,250 		746,500 -13.5% 42.50 US$31,726,250
2026-08-12 2026-08-12 PrS Proposed sale
RA Capital Healthcare Fund LP

affiliate
746,500
48.19
US$35,973,835 		746,500 48.19 US$35,973,835
2026-08-12 2026-08-12 PrS Proposed sale
RA Capital Nexus Fund III, L.P.

Affiliate
746,500
48.19
US$35,973,835 		746,500 48.19 US$35,973,835
2026-08-12 2026-08-12 PrS Proposed sale
3.2
Third Rock Ventures V, L.P.

10% Stockholder

Large shareholder
147,200
51.00
US$7,507,200 		147,200 51.00 US$7,507,200
2026-08-13 2026-08-11 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
25,000 -12.5%
44.00
US$1,100,000 		25,000 -12.5% 44.00 US$1,100,000
2026-08-11 2026-08-11 PrS Proposed sale
ELIZABETH P. BHATT

Officer

Officer
29,000
38.85
US$1,126,650 		29,000 38.85 US$1,126,650
2026-08-05 2026-08-03 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
2,334 -2.4%
34.68
US$80,944 		2,334 -2.4% 34.68 US$80,944
2026-08-05 2026-08-03 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
1,000 -1.0%
33.98
US$33,976 		1,000 -1.0% 33.98 US$33,976
2026-07-17 2026-07-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
4,000 -2.2%
33.99
US$135,974 		4,000 -2.2% 33.99 US$135,974
2026-07-15 2026-07-15 PrS Proposed sale
ELIZABETH P. BHATT

Officer

Officer
4,000
34.54
US$138,160 		4,000 34.54 US$138,160
2026-07-02 2026-07-01 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
1,233 -1.3%
34.81
US$42,926 		1,233 -1.3% 34.81 US$42,926
2026-07-02 2026-07-01 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
2,100 -2.1%
34.10
US$71,602 		2,100 -2.1% 34.10 US$71,602
2026-06-30 2026-06-29 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
2,178 -73.3%
35.18
US$76,622 		2,178 -73.3% 35.18 US$76,622
2026-06-26 2026-06-26 PrS Proposed sale
JAE KIM

Officer

Officer
2,438
36.61
US$89,243 		2,438 36.61 US$89,243
2026-06-24 2026-06-22 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
7,000 -6.8%
35.97
US$251,781 		7,000 -6.8% 35.97 US$251,781
2026-06-24 2026-06-22 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
8,000 -7.2%
35.10
US$280,801 		8,000 -7.2% 35.10 US$280,801
2026-06-22 2026-06-22 PrS Proposed sale
DANIEL LONG

Officer

Officer
25,000
36.17
US$904,250 		25,000 36.17 US$904,250
2026-06-22 2026-06-22 PrS Proposed sale
DANIEL LONG

Officer

Officer
25,000
36.17
US$904,250 		25,000 36.17 US$904,250
2026-06-22 2026-06-22 PrS Proposed sale
JAE KIM

Officer

Officer
94,339
35.26
US$3,326,120 		94,339 35.26 US$3,326,120
2026-06-22 2026-06-22 PrS Proposed sale
JAE KIM

Officer

Officer
94,339
35.26
US$3,326,120 		94,339 35.26 US$3,326,120
2026-06-16 2026-06-12 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
6,250 -88.7%
35.08
US$219,224 		6,250 -88.7% 35.08 US$219,224
2026-06-12 2026-06-12 PrS Proposed sale
SAMIRA SHAIKHLY

Officer

Officer
8,428
34.03
US$286,805 		8,428 34.03 US$286,805
2026-06-03 2026-06-01 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
2,889 -78.5%
29.66
US$85,696 		2,889 -78.5% 29.66 US$85,696
2026-06-03 2026-06-01 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
1,346 -26.8%
28.79
US$38,755 		1,346 -26.8% 28.79 US$38,755
2026-06-03 2026-06-01 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
1,700 -25.3%
27.78
US$47,231 		1,700 -25.3% 27.78 US$47,231
2026-05-28 2026-05-26 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
11,798 -93.7%
30.06
US$354,656 		11,798 -93.7% 30.06 US$354,656
2026-05-26 2026-05-26 PrS Proposed sale
SAMIRA SHAIKHLY

Officer

Officer
11,798
28.36
US$334,591 		11,798 28.36 US$334,591
2026-04-17 2026-04-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
326 -0.2%
25.86
US$8,431 		326 -0.2% 25.86 US$8,431
2026-04-17 2026-04-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
1,101 -0.6%
25.24
US$27,789 		1,101 -0.6% 25.24 US$27,789
2026-04-17 2026-04-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
2,573 -1.4%
23.76
US$61,124 		2,573 -1.4% 23.76 US$61,124
2026-03-04 2026-03-02 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
66,363 -98.8%
28.14
US$1,867,342 		66,363 -98.8% 28.14 US$1,867,342
2026-03-04 2026-03-02 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
4,090 -5.7%
27.51
US$112,496 		4,090 -5.7% 27.51 US$112,496
2026-03-02 2026-03-02 PrS Proposed sale
SAMIRA SHAIKHLY

Officer

Officer
76,388
29.02
US$2,216,780 		76,388 29.02 US$2,216,780
2026-02-20 2026-02-18 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
1,800 -1.0%
29.58
US$53,250 		1,800 -1.0% 29.58 US$53,250
2026-02-20 2026-02-18 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
2,200 -1.2%
28.46
US$62,611 		2,200 -1.2% 28.46 US$62,611
2026-02-18 2026-02-18 PrS Proposed sale
ELIZABETH BHATT

Officer

Officer
8,000
30.30
US$242,400 		8,000 30.30 US$242,400
2025-11-13 2025-11-10 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
3,501 -3.6%
18.06
US$63,223 		3,501 -3.6% 18.06 US$63,223
2025-11-10 2025-11-10 PrS Proposed sale
DANIEL DAVID LONG

Officer

Officer
3,501
18.06
US$63,223 		3,501 18.06 US$63,223
2025-03-10 2025-03-07 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
13,319 +12.8%
6.93
US$92,270 		13,319 +12.8% 6.93 US$92,270
2025-03-06 2025-03-06 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
41,355 +65.9%
6.00
US$248,130 		41,355 +65.9% 6.00 US$248,130
2025-03-06 2025-03-05 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
37,835 +151.9%
5.82
US$220,260 		37,835 +151.9% 5.82 US$220,260
2025-03-06 2025-03-04 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
7,491 +43.0%
6.35
US$47,544 		7,491 +43.0% 6.35 US$47,544
2025-02-27 2025-02-27 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
3,718 +10.2%
5.85
US$21,750 		3,718 +10.2% 5.85 US$21,750
2025-02-27 2025-02-27 B Purchase
3.5
Finer Jeffrey

CEO and President

Executive Director
3,000 +0.4%
5.80
US$17,400 		3,000 +0.4% 5.80 US$17,400
2025-02-27 2025-02-26 B Purchase
3.5
Finer Jeffrey

CEO and President

Executive Director
4,000 +0.5%
5.70
US$22,796 		4,000 +0.5% 5.70 US$22,796
2025-02-27 2025-02-25 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
6,282 +20.9%
5.59
US$35,116 		6,282 +20.9% 5.59 US$35,116
2025-02-27 2025-02-25 B Purchase
3.5
Finer Jeffrey

CEO and President

Executive Director
10,000 +1.3%
5.68
US$56,765 		10,000 +1.3% 5.68 US$56,765
2025-02-26 2025-02-24 B Purchase
3.6
Third Rock Ventures VI, L.P.
Large shareholder
18,861 +0.4%
6.00
US$113,147 		18,861 +0.4% 6.00 US$113,147
2025-02-24 2025-02-21 B Purchase
3.6
Third Rock Ventures VI, L.P.
Large shareholder
427,668 +11.4%
5.94
US$2,540,348 		427,668 +11.4% 5.94 US$2,540,348
2025-02-21 2025-02-21 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
5,000 +20.0%
5.85
US$29,250 		5,000 +20.0% 5.85 US$29,250
2025-02-24 2025-02-20 B Purchase
3.6
Third Rock Ventures VI, L.P.
Large shareholder
612,674 +19.4%
5.92
US$3,627,030 		612,674 +19.4% 5.92 US$3,627,030
2025-02-21 2025-02-20 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
14,500 +138.1%
5.88
US$85,234 		14,500 +138.1% 5.88 US$85,234
2025-02-21 2025-02-19 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
10,500 +inf%
5.51
US$57,813 		10,500 +inf% 5.51 US$57,813
2024-10-30 2024-10-28 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
341,600 +30.2%
18.00
US$6,148,800 		341,600 +30.2% 18.00 US$6,148,800
2024-10-30 2024-10-28 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
3,828,400 +225.8%
18.00
US$68,911,200 		3,828,400 +225.8% 18.00 US$68,911,200
2024-10-28 2024-10-28 B Purchase
3.2
Third Rock Ventures V, L.P.
Large shareholder
279,500 +9.7%
18.00
US$5,031,000 		279,500 +9.7% 18.00 US$5,031,000
2024-10-28 2024-10-28 B Purchase
3.2
Third Rock Ventures V, L.P.
Large shareholder
370,500 +6.3%
18.00
US$6,669,000 		370,500 +6.3% 18.00 US$6,669,000
Explore more

More insider trading research around Septerna Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America